Discontinued operations generated a profit of €241 million on an IFRS basis and €159 million on an underlying basis. The €(82) million adjustment made to the IFRS profit relates principally to:

  • 204 million capital gain on the divestment of Acetow and Vinythai.
  • €(46) million expenses related to the divestment of the polyamide activities.
  • €(36) million costs related to post-closing adjustments on the pharma divestment in 2010.